Search
for
Sort by
Research 23
- Selective Sensing of Darolutamide and Thalidomide in Pharmaceutical Preparations and in Spiked Biofluids
- Synthesis and application of clinically approved small-molecule drugs targeting androgen receptor
- Antiandrogens
- Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies
- Are sex discordant outcomes in COVID-19 related to sex hormones?
- Androgen receptor modulators: a review of recent patents and reports (2012-2018)
- COVID‐19, androgens, and androgenic alopecia
- Sexual dimorphism of COVID-19 inspires drug repositioning and host-targeting immunotherapy for viral pneumonia
- Hétérogénéité tumorale du cancer de la prostate et infection par le SARS-CoV2 : une relation complexe impliquant les vésicules extracellulaires et le récepteur des androgènes
- Enhanced ex vivo skin retention of bicalutamide using a nano-in-micro composite: Drug-loaded lipid vesicles in a dissolving microarray patch
- Bicalutamide: A review
- Table_2.docx
- Table_1.docx
- Androgen sensitivity gateway to COVID‐19 disease severity
- Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The “Gabrin sign”
- Newly Developed Targeted Therapies Against the Androgen Receptor in Triple-Negative Breast Cancer: A Review
- Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial
- Do Anti-androgens Have Potential as Therapeutics for COVID-19?
- Analyzing the role of ACE2, AR, MX1 and TMPRSS2 genetic markers for COVID-19 severity
- Antiandrogens as Therapies for COVID-19: A Systematic Review
- Use of Antiandrogens as Therapeutic Agents in COVID-19 Patients
- Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy
- Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer